These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 17136224

  • 1. Natalizumab.
    Berger JR.
    Drugs Today (Barc); 2006 Oct; 42(10):639-55. PubMed ID: 17136224
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R.
    N Engl J Med; 2009 Sep 10; 361(11):1075-80. PubMed ID: 19741228
    [Abstract] [Full Text] [Related]

  • 4. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 10; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 5. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
    Major EO.
    N Engl J Med; 2009 Sep 10; 361(11):1041-3. PubMed ID: 19741226
    [No Abstract] [Full Text] [Related]

  • 6. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.
    N Engl J Med; 2005 Jul 28; 353(4):375-81. PubMed ID: 15947078
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
    Bennett JL.
    Neurol Res; 2006 Apr 28; 28(3):291-8. PubMed ID: 16687056
    [Abstract] [Full Text] [Related]

  • 8. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
    Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P.
    N Engl J Med; 2005 Jul 28; 353(4):362-8. PubMed ID: 15947080
    [Abstract] [Full Text] [Related]

  • 9. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.
    Mult Scler; 2013 Dec 28; 19(14):1826-40. PubMed ID: 24192217
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.
    Lancet Neurol; 2010 Apr 28; 9(4):438-46. PubMed ID: 20298967
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK, Tyler KL.
    N Engl J Med; 2005 Jul 28; 353(4):369-74. PubMed ID: 15947079
    [Abstract] [Full Text] [Related]

  • 13. Fatalities in natalizumab treatment--a 'no go' for leukocyte recirculation approaches?
    Li YY, Perez HD, Zollner TM.
    Expert Opin Ther Targets; 2006 Aug 28; 10(4):489-99. PubMed ID: 16848686
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
    Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB.
    N Engl J Med; 2006 Mar 02; 354(9):924-33. PubMed ID: 16510746
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2007 Oct 02; 1(1):29-39. PubMed ID: 19072431
    [Abstract] [Full Text] [Related]

  • 16. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab therapy for multiple sclerosis.
    Derfuss T, Kuhle J, Lindberg R, Kappos L.
    Semin Neurol; 2013 Feb 17; 33(1):26-36. PubMed ID: 23709210
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
    Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major EO, Clifford DB.
    Lancet Neurol; 2007 May 17; 6(5):431-41. PubMed ID: 17434098
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical?
    Arnaud FX, Hissene A, Métivier D, Dutasta F, Berets O, N'guema B, A'teriitéhau C, Baccialone J, Potet J.
    J Neuroradiol; 2012 Oct 17; 39(4):267-70. PubMed ID: 22341620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.